Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients

Patients must have a diagnosis of metastatic cancer. Patients currently on oxycodone/acetaminophen are eligible as long as they are on the 5 mg/325 mg dose. Patients currently on another opiate, who have been prescribed or will be prescribed oxycodone/acetaminophen as an addition to their therapy are also eligible. Patients must have a worst pain score of at least 3 (on a scale of 0-10) on the Brief Pain Inventory (BPI)* within 3 days prior to registration and be deemed by their physician to require initiation, continuation, or uptitration of opioid therapy with oxycodone/acetaminophen 5mg/325mg.
Patients must be >/= 18 years of age; must complete baseline PROs prior to registration; must be able to read English, must be willing to participate in electronic data collection and just have an iPhone, Android phone, or tablet with cellular connectivity and must have successfully downloaded the Proteus Discover App. Patients must not have a known allergy to adhesive tape, hydrogel or conductive get or hydrocolloid; Women must not be pregnant or nursing. Patients of reproductive potential must have agreed to use an effective contraceptive method.